Absci Corp

Absci uses generative AI plus lab automation to design therapeutic antibodies from scratch, aiming to create drug candidates faster than traditional discovery and to partner them out or advance its own.

Ticker

ABSI

Company

Absci Corp

Exchange

Nasdaq

Listing

listed

Sector

Biotech / AI Drug Discovery

On X, $ABSI is framed as the same shovels-not-gold platform bet as AbCellera, one layer deeper: where AbCellera screens nature for antibodies, Absci designs them de novo with AI, so the bull case is earlier on the curve with more optionality.

• Absci Corp is listed on Nasdaq under the ticker ABSI and files reports with the U.S. SEC.S1
• Absci uses generative AI plus lab automation to design therapeutic antibodies de novo (from scratch), then partners them out or advances its own programs.S2
• In fiscal year 2025 Absci reported revenue of about $2.8 million (down from $4.5 million in 2024) and a net loss of about $115.2 million, or $(0.84) per share, with research and development expense of about $81.4 million.S2
• As of December 31, 2025 Absci held about $144.3 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the first half of 2028.S2
• Absci's lead program ABS-201, in androgenetic alopecia, is in a Phase 1/2a trial (HEADLINE), with an interim efficacy readout guided for the second half of 2026.S2

• narrativeHigher-beta cousin framing: de-novo AI design is earlier-stage than screening-based discovery, which the bull case reads as more upside and the bear case as less proven.
• narrativeBull case as it circulates: a single AI-designed asset reaching the clinic with strong data would validate the whole generative platform, not just the molecule.

• ▸Absci is earlier in validation than screening-based peers, generated only about $2.8 million of revenue against a roughly $115.2 million net loss in 2025, and depends on partner uptake plus clinical and regulatory execution. Clinical-stage cash burn implies potential future dilution.S2

Generative AI drug design (de novo)

— Using AI models to design a new antibody from scratch toward a target, rather than searching for one that already exists in nature.

Higher beta

— Tends to move more sharply than the broader market or a more established peer, more upside in good scenarios, more downside in bad ones.